A vaccine that can kill cancer

Israeli company formulates a drug that ‘trains’ the immune system to seek and destroy malignant cells that have already invaded the body.

Cancer cells

Cancer cells.

As we get older, modern medicine will help more of us live with cancer rather than die from it. That’s the assumption behind a vaccine to treat cancer, being developed by a pharmaceutical company in Israel.

Vaxil BioTherapeutics’ main product, ImMucin, is now in advanced clinical trials at Hadassah University Medical Center in Jerusalem.

CEO Julian Levy tells ISRAEL21c that this therapeutic vaccine doesn’t prevent cancer from invading, but activates and enhances the body’s natural immune system to seek and destroy cancer cells already present in the body, such as those lingering after cancer surgery.

Malignant cells normally get out of control by tricking the immune system not to notice them, a strategy that works especially well in older people because immune systems get less efficient with age.


The vaccine is currently being tested against a blood cancer called multiple myeloma. However, Vaxil’s scientific breakthrough is based on a drug platform, VaxHit, which can be tailored to treat not only 90 percent of cancers, he says, but also diseases such as tuberculosis.

This disease is cropping up in developing nations as existing vaccines are proving less and less effective.

“Two billion are affected by the pathogen,” says Levy. “Ten percent will develop the active disease. And while TB can be treated by drugs, it takes several months and it can be brutal.”

CEO Julian Levy

Julian Levy, CEO of Vaxil BioTherapeutics.

According to Levy, the vaccine presents no side effects, and can be taken indefinitely, like vitamins. ImMucin is designed to overcome cancer cells that mutate, rendering other drugs ineffective.

A hit for long-term survival

Depending on the outcome of clinical trials, the ImMucin vaccine could be ready and marketable within the next six years. It could have major implications for the treatment of leading killers like prostate and breast cancer.

New studies in the United States suggest that fewer men will go under the scalpel to remove their cancerous prostate gland, and simply live with the usually slow-growing cancer. Vaxil could be a helpful tool in prolonging lives of these patients.

The specific molecular markers on most cancer cells, which ImMucin “trains” the immune system’s T-cells to find and kill, were discovered by the company’s founder, Dr. Lior Carmon, a biotechnology entrepreneur with a doctorate in immunology from the Weizmann Institute of Science in Rehovot.

Vaxil was founded in 2006, and the company of five is currently based in Nes Ziona, Israel. This year, Vaxil signed a memorandum of understanding to merge its business into Sheldonco, an Israeli company traded on the Tel Aviv Stock Exchange.

About Karin Kloosterman

Karin Kloosterman is an award-winning environment news publisher who founded Green Prophet (www.greenprophet.com) to connect North Americans to issues that matter in the Middle East. She is the CEO of the Internet of Things startup flux, a company that is making social grow tools for urban farmers everywhere (www.fluxiot.com). Karin can be reached at karin (at) fluxiot.com.
  • Barbara D Holtzman

    Available in 6 years? Only in Israel. You think it’s a good thing? Only for people. Big Pharma and Big Medicine don’t care about people. This will shake their profit foundations – unless they can make money off of it. If that’s the case, it should be worldwide as soon as they can pay for approvals and rush it to market.

  • nusret ercan

    How can we get to buy vaxil,can you help please.

  • Lucy Fer

    Vaxil has published divulgation articles with this head several times.
    This is not a vaccine that can kill cancer. This is an immunotherapeutic treatment that can have effects on cancer, we will see.
    Immunotherapeutic treatments are called sometimes immunovaccines, but they are not vaccines as we know them.
    With lots of good luck, in some 7-10 years, they will have a treatment for multiple myeloma where they just finished phase I/II. Phase IIb is not ready yet.
    Regarding prostate, that you mention on your article, no clinical trials have been done.
    These two guys repeat their false statements once and again, mixed with some true.
    Israel21C should not be accomplice of lies and public misguiding.
    Please stop the Vaxil lies. People deserve better.

    You should withdraw this article, for the sake of honesty.

    PS: everything that I wrote is based on the disclosures at Vaxil’s website.